Clinical Trial

This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax Malaria

Study acronym: SJ733-2002
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this Phase 2b study is to examine the safety and efficacy of the combination of SJ733, an investigational agent, and tafenoquine for the radical cure of uncomplicated P. vivax malaria monoinfection in adult participants and determine the contributions of SJ733 to the effect. SJ733 will be administered in a 1-, 2-, or 3-day treatment schedule in combination with a single dose of tafenoquine.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-02-18; most recent amendment 2026-05-22.
Trial Details
NCT Number NCT07430592
Lead Sponsor R. Kiplin Guy
Collaborators: Global Health Innovative Technology Fund, Congressionally Directed Medical Research Programs, University of Minnesota
Conditions Malaria, Malaria Vivax, Radical Cure
Enrollment 104 participants
Start Date 2026-10-01
Primary Completion 2028-11-20 (estimated)
Study Completion 2028-11-20 (estimated)
Updated on ClinicalTrials.gov 2026-07-30